Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts.
Recent clinical studies indicate that the use of aspirin and dipyridamole improves graft patency rates in patients with infrainguinal polytetrafluoroethylene (PTFE) grafts and aortocoronary vein grafts. We undertook a prospective, double-blind, randomized study to determine whether these drugs administered postoperatively to patients with PTFE or autologous vein infrainguinal bypasses would improve graft patency during the first 24 months after operation. Patients received either aspirin 325 mg and dipyridamole 75 mg or identical placebo tablets three times a day, taken orally. Patency rates were compared by computing standard life tables and comparing cumulative patency rates. One hundred patients with 102 grafts were studied. The cumulative patency rate at 24 months was not significantly different for the treatment (57%) versus control (67%) groups or for any subgroup. We conclude that aspirin and dipyridamole administered postoperatively in the doses used in this study do not improve the overall patency rates of vein or PTFE infrainguinal bypass grafts.
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D001807:Blood Vessel Prosthesis; D004176:Dipyridamole / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007383:Intermittent Claudication / Q000601:surgery*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene; D011182:Postoperative Care; D011446:Prospective Studies; D011897:Random Allocation; D012501:Saphenous Vein / Q000637:transplantation; D013997:Time Factors
D004176:Dipyridamole; D011138:Polytetrafluoroethylene; D001241:Aspirin